The microtubule as a breast cancer target

Breast Cancer

Volumn 18, Issue 2, 2011, Pages 103-119

  Higa, Gerald M ^a,b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Tubulin; Tubulin; Dynamic instability; Microtubule

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPOTHILONE DERIVATIVE; FLUOROURACIL; IXABEPILONE; LAPATINIB; MAYTANSINE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VASCULAR TARGETING AGENT; VINBLASTINE; VINCA ALKALOID;

ARTHRALGIA; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONSTIPATION; DOSE RESPONSE; DRUG BINDING SITE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL SYMPTOM; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEUKOPENIA; LIVER FUNCTION TEST; MICROTUBULE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH DISEASE; THROMBOCYTOPENIA; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; BLOOD VESSELS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; HUMANS; MAYTANSINE; MICROTUBULES; TAXOIDS; VINCA ALKALOIDS;

EID: 79956371053     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-010-0224-7     Document Type: Review

References (141)

1. D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70 10647931 1:CAS:528:DC%2BD3cXks1CktA%3D%3D (Pubitemid 30046295)
2. Surveillance Epidemiology and End Results. SEER stat fact sheets: breast cancer. SEER Cancer Statistics Review 1975-2005. http://seer.concer.gov/ statfacts/html/breast.html. Accessed 7 Apr 2010.
3. E Nogales SG Wolf KH Downing 1998 Structure of the αβ tubulin dimer by electron crystallography Nature 391 199 202 9428769 1:CAS:528:DyaK1cXmt1Kisw%3D%3D
4. J Rassow O von Ahsen U Bömer N Pfanner 1997 Molecular chaperones: towards a characterization of the heat-shock protein 70 family Trends Cell Biol 7 129 133 1:CAS:528:DyaK2sXhvFCmu7o%3D (Pubitemid 27100042)
5. D Hirata H Masuda M Eddison T Toda 1998 Essential role of tubulin-folding cofactor D in microtubule assembly and its association with microtubules in fission yeast EMBO J 17 667 676
6. E Nogales M Whittaker RA Milligan KH Downing 1999 High-resolution model of the microtubule Cell 96 79 88 9989499 1:CAS:528:DyaK1MXmslagtA%3D%3D (Pubitemid 29044155)
7. A Desai TJ Mitchison 1997 Microtubule polymerization dynamics Annu Rev Cell Dev Biol 13 83 117 9442869 1:CAS:528:DyaK1cXisFSksg%3D%3D (Pubitemid 28034521)
8. RA Walker S Inoue ED Salmon 1989 Asymmetric behavior of severed microtubule ends after ultraviolet-microbeam irradiation of individual microtubules in vitro J Cell Biol 108 931 937 2921286 1:CAS:528: DyaL1MXhs1ymsb8%3D (Pubitemid 19083744)
9. E Nogales 2000 Structural insights into microtubule function Annu Rev Biochem 69 277 302 10966460 1:CAS:528:DC%2BD3cXnt1ajtb4%3D
10. R Dhamodharan MA Jordan D Thrower L Wilson P Wadsworth 1995 Vinblastine suppresses dynamics of individual microtubules in living interphase cells Mol Biol Cell 6 1215 1229 8534917 1:CAS:528:DyaK2MXotV2ltrg%3D
11. WD Singer MA Jordan L Wilson RH Himes 1989 Binding of vinblastine to stabilized microtubules Mol Pharmacol 36 366 370 2571072 1:CAS:528: DyaL1MXmtVyrs70%3D (Pubitemid 19245381)
12. SS Rai J Wolff 1996 Localization of the vinblastine binding site on β-tubulin J Biol Chem 271 14707 14711 8663038 1:CAS:528:DyaK28XjvVWmsLs%3D (Pubitemid 26194946)
13. S Rao NE Krauss JM Heerding CS Swindell I Ringel GA Orr, et al. 1994 3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin J Biol Chem 269 3132 3134 7906266 1:CAS:528:DyaK2cXhvVKhtbY%3D
14. A Romero MG Rabinovich CT Vallejo JE Perez R Rodriguez MA Cuevas, et al. 1994 Vinorelbine as first-line chemotherapy for metastatic breast carcinoma J Clin Oncol 12 336 341 8113840 1:STN:280:DyaK2c7lslKisw%3D%3D (Pubitemid 24056407)
15. CJ Twelves NA Dobbs A Curnow RE Coleman AL Stewart CJ Tyrrell, et al. 1994 A phase II multicentre, UK study of vinorelbine in advanced breast cancer Br J Cancer 70 990 993 7947109 1:STN:280:DyaK2M%2FjsVSksA%3D%3D (Pubitemid 24331101)
16. J García-Conde A Lluch M Martin A Casado H Gervasio C De Oliveira, et al. 1994 Phase II trial of weekly i.v. vinorelbine in first-line advanced breast cancer chemotherapy Ann Oncol 5 854 857 7848890 (Pubitemid 24341882)
17. S Woodard PC Nadella L Kotur J Wilson WE Burak CL Shapiro 2003 Older women with breast carcinoma are less likely to receive adjuvant chemotherapy: evidence of possible age bias? Cancer 98 1141 1149 12973837 (Pubitemid 37099898)
18. C Vogel M O'Rourke E Winer H Hochster A Chang B Adamkiewicz, et al. 1999 Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older Ann Oncol 10 397 402 10370781 1:STN:280: DyaK1M3pvV2iuw%3D%3D (Pubitemid 29236416)
19. HJ Burstein I Kuter SM Campos RS Gelman L Tribou LM Parker, et al. 2001 Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer J Clin Oncol 19 2722 2730 11352965 1:CAS:528:DC%2BD3MXkt1Omu7k%3D (Pubitemid 32441378)
20. M Pegram S Hsu G Lewis R Pietras M Beryt M Sliwkowski, et al. 1999 Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 18 2241 2251 10327070 1:CAS:528:DyaK1MXis12murk%3D (Pubitemid 29186925)
21. FM Sirotnak KD Danenberg J Chen F Fritz PV Danenberg 2000 Markedly decreased binding of vincristine to tubulin in vinca alkaloid-resistant Chinese hamster cells is associated with selective overexpression of α and β isoforms Biochem Biophys Res Commun 269 21 24 10694470 1:CAS:528: DC%2BD3cXhtl2rsr0%3D (Pubitemid 30440247)
22. WB Derry L Wilson IA Khan RF Luduena MA Jordan 1997 Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes Biochemistry 36 3554 3562 9132006 1:CAS:528:DyaK2sXitVGjt7Y%3D (Pubitemid 27143509)
23. S Ranganathan DW Dexter CA Benetatos AE Chapman KD Tew GR Hudes 1996 Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance Cancer Res 56 2584 2589 8653701 1:CAS:528:DyaK28XjtlCgur0%3D
24. RB Montgomery J Guzman DM O'Rourke WL Stahl 2000 Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression J Biol Chem 275 17358 17363 10749863 1:CAS:528:DC%2BD3cXktFaks7o%3D (Pubitemid 30430771)
25. CC Zhang JM Yang E White M Murphy A Levine WN Hait 1998 The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells Oncogene 16 1617 1624 9569030 1:CAS:528:DyaK1cXis1eju7s%3D (Pubitemid 28159910)
26. SJ Chapin CM Lue MT Yu JC Bulinski 1995 Differential expression of alternatively spliced forms of MAP4: a repertoire of structurally different microtubule-binding domains Biochemistry 34 2289 2301 7857940 1:CAS:528:DyaK2MXjs1Cgtbo%3D
27. Y Shen T Shenk 1994 Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein Proc Natl Acad Sci USA 91 8940 8944 8090749 1:CAS:528:DyaK2cXmt1Ogt74%3D
28. P Sabbatim F McCormick 1999 Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis J Biol Chem 274 24263 24269
29. BP Zhou Y Liao W Xia Y Zou B Spohn M-C Hung 2001 HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation Nat Cell Biol 3 973 982 11715018 1:CAS:528:DC%2BD3MXosVeqsLo%3D (Pubitemid 34428742)
30. S Remillard LI Rebhun GA Howie SM Kupchan 1975 Antimitotic activity of the potent tumor inhibitor maytansine Science 189 1002 1005 1241159 1:CAS:528:DyaE2MXlvVyht7k%3D
31. RV Chari BA Martell JL Gross SB Cook SA Shah WA Blättler, et al. 1992 Immunoconjugates containing novel maytansinoids: promising anticancer drugs Cancer Res 52 127 131 1727373 1:CAS:528:DyaK38Xht1Snu7s%3D
32. B Bhattacharyya J Wolff 1977 Maytansine binding to the vinblastine sites of tubulin FEBS Lett 75 159 162 852577 1:CAS:528:DyaE2sXktFGksbs%3D (Pubitemid 8080301)
33. SM Kupchan AT Sneden AR Branfman GA Howie LI Rebhun WE McIvor, et al. 1978 Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids J Med Chem 21 31 37 563462 1:STN:280:DyaE1c%2FmvFSqtA%3D%3D
34. RH Blum BK Wittenberg GP Canellos RJ Mayer AT Skarin IC Henderson, et al. 1978 A therapeutic trial of maytansine Cancer Clin Trials 1 113 117 757139 1:STN:280:DyaL3c%2FptVagsQ%3D%3D
35. RT Eagan JN Ingle J Rubin S Frytak CG Moertel 1978 Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication J Natl Cancer Inst 60 93 96 628025 1:STN:280:DyaE1c7htFGjsw%3D%3D (Pubitemid 8287174)
36. Beeram M, Burris HA, Modi S, Birkner M, Girish S, Tibbitts J, et al. A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate (ADC), given every 3 weeks to patients with HER2+ metastatic breast cancer. J Clin Oncol. 2008;26:15S (Abstract 1028).
37. Vogel CL, Burris HA, Limentani S, Borson R, O'Shaughnessy J, Vukelja S, et al. A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): final results. J Clin Oncol. 2009;27:15s (Abstract 1017).
38. Krop I, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer who were previously treated with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. Presented at San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, December 9-13, 2009 (Abstract 710).
39. TH Wang HS Wang YK Soong 2000 Paclitaxel-induced cell death: where the cell cycle and apoptosis come together Cancer 88 2619 2628 10861441 1:CAS:528:DC%2BD3cXktFGjsLc%3D
40. KL Donaldson G Goolsby PA Kiener AF Wahl 1994 Activation of p34cdc2 coincident with taxol-induced apoptosis Cell Growth Differ 5 1041 1050 7848905 1:CAS:528:DyaK2cXmslWnu78%3D (Pubitemid 24312279)
41. G Shaulsky N Goldfinger MS Tosky AJ Levine V Rotter 1991 Nuclear localization is essential for the activity of p53 protein Oncogene 6 2055 2065 1719467 1:CAS:528:DyaK38Xls1agtw%3D%3D (Pubitemid 21924047)
42. EK Rowinsky RC Donehower RJ Jones RW Tucker 1988 Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol Cancer Res 48 4093 4100 2898289 1:CAS:528:DyaL1cXkvVGrurc%3D
43. J Carmichael WG Degraff AF Gazdar JD Minna JB Mitchell 1987 Evaluation of a tetrazolium based semi-automated colorimetric assay: I. Assessment of chemosensitivity testing Cancer Res 47 936 942 3802100 1:CAS:528: DyaL2sXhsVyrtb0%3D (Pubitemid 17027905)
44. ®) in human tumour cell lines Br J Cancer 68 1104 1109 7903152 1:CAS:528:DyaK2cXivV2mtrw%3D (Pubitemid 23356660)
45. JE Liebmann JA Cook C Lipschulz D Teague J Fisher JB Mitchell 1994 The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines Cancer Chemother Pharmacol 33 331 339 7904231 1:CAS:528:DyaK2cXls12qsb4%3D
46. C Dumontet BI Sikic 1999 Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death J Clin Oncol 17 1061 1070 10071301 1:CAS:528:DyaK1MXhvFGnsr8%3D (Pubitemid 29109340)
47. AR Hanauske D Degen SG Hilsenbeck MC Bissery DD Von Hoff 1992 Effects of taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells Anticancer Drugs 3 121 124 1356030 1:CAS:528:DyaK38XktVSntLY%3D
48. V Valero SE Jones DD Von Hoff DJ Booser RG Mennel PM Ravdin, et al. 1998 A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer J Clin Oncol 16 3362 3368 9779713 1:CAS:528:DyaK1cXmvFGrtbc%3D (Pubitemid 28481633)
49. CF Verschraegen T Sittisomwong AP Kudelka E Guedes M Steger T Nelson-Taylor, et al. 2000 Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma J Clin Oncol 18 2733 2739 10894873 1:CAS:528: DC%2BD3cXls12iu7k%3D (Pubitemid 30463556)
50. M Bontenbal GJ Creemers HJ Braun AC de Boer JT Janssen RB Leys, et al. 2005 Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre J Clin Oncol 23 7081 7088 16192591 1:CAS:528:DC%2BD2MXhtFCrsbbJ
51. JM Nabholtz C Falkson D Campos J Szanto M Martin S Chan, et al. 2003 Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial J Clin Oncol 21 968 975 12637459 1:CAS:528:DC%2BD2cXpsVGqs7g%3D (Pubitemid 46594123)
52. J Jassem T Pienkowski A Pluzanska S Jelic V Gorbunova Z Mrsic-Krmpotic, et al. 2001 Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial J Clin Oncol 19 1707 1715 11251000 1:CAS:528:DC%2BD3MXisFygs70%3D (Pubitemid 32230871)
53. J Gehl M Boesgaard T Paaske B Vittrup Jensen P Dombernowsky 1996 Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic Ann Oncol 7 687 693 8905026 1:STN:280:DyaK2s%2FmtV2rsg%3D%3D (Pubitemid 26323541)
54. L Gianni L Viganò A Locatelli G Capri A Giani E Tarenzi, et al. 1997 Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer J Clin Oncol 15 1906 1915 9164201 1:CAS:528:DyaK2sXjsVCks7k%3D (Pubitemid 27209520)
55. D Amadori GL Frassineti W Zoli C Milandri P Serra A Tienghi, et al. 1997 A phase I/II study; doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer Oncology 11 30 33 9144688 1:STN:280:DyaK2s3ovF2jsQ%3D%3D (Pubitemid 27380991)
56. L Gianni E Munzone G Capri F Fulfaro E Tarenzi F Villani, et al. 1995 Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study J Clin Oncol 13 2688 2699 7595726 1:CAS:528:DyaK28XitlGmsQ%3D%3D
57. P Dombernowsky J Gehl M Boesgaard TP Jensen BV Jensen 1995 Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer Semin Oncol 22 Suppl 15 13 17 8643964 1:CAS:528:DyaK28Xhs1eltrY%3D (Pubitemid 26057248)
58. L Biganzoli T Cufer P Bruning R Coleman L Duchateau AH Calvert, et al. 2002 Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial J Clin Oncol 20 3114 3121 12118025 1:CAS:528:DC%2BD38XmtVCrtb8%3D (Pubitemid 34791101)
59. L Biganzoli T Cufer P Bruning RE Coleman L Duchateau B Rapoport, et al. 2003 Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial Cancer 97 40 45 12491503 1:CAS:528:DC%2BD3sXmsFyktg%3D%3D (Pubitemid 36033861)
60. L Gianni P Dombernowsky G Sledge M Martin D Amadori SG Arbuck, et al. 2001 Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer Ann Oncol 12 1067 1073 11583187 1:STN:280:DC%2BD3MrjsFeiug%3D%3D (Pubitemid 32834486)
61. Luck H, Thomssen C, Untch M, Kuhn W, Eidtmann H, du Bois A, et al. Multicenter phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group. J Clin Oncol. 2000;19:73a (Abstract 280).
62. D Ghersi N Wilcken RJ Simes 2005 A systematic review of taxane-containing regimens for metastatic breast cancer Br J Cancer 93 293 301 16052223 1:CAS:528:DC%2BD2MXmvFensL0%3D (Pubitemid 43080031)
63. MJ Piccart-Gebhart T Burzykowski M Buyse G Sledge J Carmichael HJ Lück, et al. 2008 Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer J Clin Oncol 26 1980 1986 18421049 1:CAS:528:DC%2BD1cXlvFaqs7w%3D
64. M De Laurentiis G Cancello D D'Agostino M Giuliano A Giordano E Montagna, et al. 2008 Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials J Clin Oncol 26 44 53 18165639
65. M Martin T Pienkowski J Mackey M Pawlicki JP Guastalla C Weaver, et al. 2005 Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2302 2313 15930421 1:CAS:528:DC%2BD2MXksl2lt7c%3D (Pubitemid 40740554)
66. HD Bear S Anderson RE Smith CE Geyer Jr EP Mamounas B Fisher, et al. 2006 Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27 J Clin Oncol 24 2019 2027 16606972 1:CAS:528:DC%2BD28Xlt1amur0%3D (Pubitemid 46622110)
67. H Roché P Fumoleau M Spielmann JL Canon T Delozier D Serin, et al. 2006 Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial J Clin Oncol 24 5664 5671 17116941 (Pubitemid 46631307)
68. ®) J Biol Chem 272 2534 2541 8999970 1:CAS:528:DyaK2sXotFCitw%3D%3D (Pubitemid 27058547)
69. P Giannakakou R Gussio E Nogales KH Downing D Zaharevitz B Bollbuck, et al. 2000 A common pharmacophore for epothilones and taxanes: a molecular basis for drug resistance conferred by tubulin mutations in human cancer cells Proc Natl Acad Sci 97 2904 2909 10688884 1:CAS:528:DC%2BD3cXitVahtrk%3D (Pubitemid 30159270)
70. FY Lee R Borzilleri CR Fairchild SH Kim BH Long C Reventos-Suarez, et al. 2001 BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy Clin Cancer Res 7 1429 1437 11350914 1:CAS:528:DC%2BD3MXktlels7Y%3D (Pubitemid 32708699)
71. S Mani HM McDaid A Grossman F Muggia S Goel T Griffin, et al. 2007 Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone analogue, ixabepilone Ann Oncol 18 190 195 17018704 1:STN:280:DC%2BD2s%2FisVWguw%3D%3D (Pubitemid 46152521)
72. E Thomas J Tabernero M Fornier P Conté P Fumoleau A Lluch, et al. 2007 Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer J Clin Oncol 25 3399 3406 17606975 1:CAS:528:DC%2BD2sXhtVajsb%2FN (Pubitemid 47310875)
73. EA Perez G Lerzo X Pivot E Thomas L Vahdat L Bosserman, et al. 2007 Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to anthracycline, a taxane, and capecitabine J Clin Oncol 25 3407 3414 17606974 1:CAS:528:DC%2BD2sXhtVajsb%2FP (Pubitemid 47310876)
74. H Roché L Yelle F Cognetti L Mauriac C Bunnell J Sparano, et al. 2007 Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy J Clin Oncol 25 3415 3420 17606972 (Pubitemid 47310877)
75. N Denduluri JA Low JJ Lee AW Berman JM Walshe U Vatas, et al. 2007 Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes J Clin Oncol 25 3421 3427 17606971 1:CAS:528:DC%2BD2sXhtVajsb%2FE (Pubitemid 47310878)
76. ES Thomas HL Gomez RK Li HC Chung LE Fein VF Chan, et al. 2007 Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 5210 5217 17968020 1:CAS:528:DC%2BD2sXhsVKnsbzO (Pubitemid 350232252)
77. Lee FY, Camuso A, Castenada C, Flefleh I, Ingio D, Kan K, et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma. J Clin Oncol. 2006;24:18s (Abstract 12017).
78. T Korb K Schlüter A Enns HU Spiegel N Senninger GL Nicolson, et al. 2004 Integrity of actin fibers and microtubules influences metastatic tumor cell adhesion Exp Cell Res 299 236 247 15302590 1:CAS:528:DC%2BD2cXmsVKgu7Y%3D (Pubitemid 39078398)
79. SA Hill SJ Lonergan J Denekamp DJ Chaplin 1993 Vinca alkaloids: anti-vascular effects in a murine tumour Eur J Cancer 9 1320 1324 (Pubitemid 23169906)
80. Y Nihei M Suzuki A Okano T Tsuji Y Akiyama T Tsuruo, et al. 1999 Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy Jpn J Cancer Res 90 1387 1395 10665658 1:CAS:528: DC%2BD3cXpslCrsQ%3D%3D (Pubitemid 30032079)
81. W Landuyt O Verdoes DO Darius M Drijkoningen S Nuyts J Theys, et al. 2000 Vascular targeting of solid tumours: a major "inverse" volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas Eur J Cancer 36 1833 1843 10974632 1:CAS:528: DC%2BD3cXmtF2jt7g%3D (Pubitemid 30639504)
82. GM Tozer VE Prise J Wilson RJ Locke B Vojnovic MR Stratford, et al. 1999 Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues Cancer Res 59 1626 1634 10197639 1:CAS:528:DyaK1MXisVWku7s%3D (Pubitemid 29160136)
83. SE Holwell PA Cooper MJ Thompson GR Pettit LW Lippert 3rd SW Martin, et al. 2002 Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti-vascular effects in experimental tumours Anticancer Res 22 707 711 12017147 1:CAS:528:DC%2BD38XktF2ntbg%3D (Pubitemid 34475218)
84. DC Blakey SE Ashton FR Westwood M Walker AJ Ryan 2002 ZD6126: a novel small molecule vascular targeting agent Int J Radiat Oncol Biol Phys 54 1497 1502 12459377 1:CAS:528:DC%2BD38XovFKjsbg%3D (Pubitemid 35380055)
85. L-M Ching WR Joseph KE Crosier BC Baguley 1994 Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4 acetic acid (NSC 640488) Cancer Res 54 870 872 8313372 1:CAS:528:DyaK2cXitVyjurk%3D (Pubitemid 24085430)
86. MB Bunge 1986 The axonal cytoskeleton: its role in generating and maintaining cell form Trends Neurosci 9 477 482
87. RB Campenot K Lund DL Senger 1996 Delivery of newly synthesized tubulin to rapidly growing distal axons of rat sympathetic neurons in compartmented cultures J Cell Biol 135 701 709 8909544 1:CAS:528:DyaK28Xms1Khtr0%3D (Pubitemid 26372926)
88. M Mercken I Fischer KS Kosik RA Nixon 1995 Three distinct axonal transport rates for tau, tubulin, and other microtubule-associated proteins J Neurosci 15 8259 8267 8613759 1:CAS:528:DyaK28Xls1ym
89. RD Lobato 2008 Historical vignette of Cajal's work "Degeneration and regeneration of the nervous system" with a reflection of the author Neurocirugia 19 456 468 18936864 1:STN:280:DC%2BD1cnnsFSjtQ%3D%3D
90. KM Yamada BS Spooner NK Wessells 1970 Axon growth: roles of microfilaments and microtubules Proc Natl Acad Sci USA 66 1206 1212 5273449 1:CAS:528:DyaE3MXitFWmsA%3D%3D
91. A Hughes 1953 The growth of embryonic neurites; a study of cultures of chick neural tissues J Anat 87 150 162 13044726 1:STN:280:DyaG3s%2FmvFGmtQ%3D%3D
92. WW Schlaepfer J Bruce 1990 Neurofilament proteins are distributed in a diminishing proximodistal gradient along rat sciatic nerve J Neurochem 55 453 460 2115070 1:CAS:528:DyaK3cXkvFGhtL8%3D
93. EW Dent FB Gertler 2003 Cytoskeletal dynamics and transport in growth cone motility and axon guidance Neuron 40 209 227 14556705 1:CAS:528: DC%2BD3sXosFCru7c%3D (Pubitemid 37244093)
94. Te Loo DM, van Schie RM, Hoogerbrugge PM. Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 2009;27:15s (Abstract 10049).
95. A Al Ferayan NA Russell M Al Wohaibi A Awada B Scherman 1999 Cerebrospinal fluid lavage in the treatment of inadvertent intrathecal vincristine injection Childs Nerv Syst 15 87 89 10230662 1:STN:280: DyaK1M3ksFKqsQ%3D%3D (Pubitemid 29187569)
96. EA Neuwelt 2004 Mechanisms of disease: the blood-brain barrier Neurosurgery 54 131 142 14683550 (Pubitemid 38040866)
97. EK Rowinsky PJ Burke JE Karp RW Tucker DS Ettinger RC Donehower 1989 Phase I study of taxol in refractory adult acute leukemia Cancer Res 49 4640 4647 2568175 1:STN:280:DyaL1Mzgtl2jsw%3D%3D (Pubitemid 19208374)
98. A Ertürk F Hellal J Enes F Bradke 2007 Disorganized microtubules underlie the formation of retraction bulbs and the failure of axonal regeneration J Neurosci 27 9169 9180 17715353 (Pubitemid 47312058)
99. DB Murphy GG Borisy 1975 Association of high-molecular-weight proteins with microtubules and their role in microtubule assembly in vitro Proc Natl Acad Sci USA 72 2696 2700 1058484 1:CAS:528:DyaE2MXlsVegsrw%3D
100. R Levi-Montalcini B Booker 1960 Excessive growth of the sympathetic ganglia evoked by a protein isolated from mouse salivary glands Proc Natl Acad Sci USA 46 373 384 16578496 1:CAS:528:DyaF3cXmvVeqtg%3D%3D
101. JC Vickers JH Morrison VL Friedrich Jr GA Elder DP Perl RN Katz, et al. 1994 Age-associated and cell-type-specific neurofibrillary pathology in transgenic mice expressing the human midsized neurofilament subunit J Neurosci 14 5603 5612 8083756 1:STN:280:DyaK2czmsFOjsw%3D%3D (Pubitemid 24279076)
102. TM Svitkina AB Verkhovsky GG Borisy 1996 Plectin sidearms mediate interaction of the intermediate filaments with microtubules and other components of the cytoskeleton J Cell Biol 135 991 1007 8922382 1:CAS:528: DyaK28XntVarsL0%3D (Pubitemid 26403774)
103. JR Stanley 1993 Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion Adv Immunol 53 291 325 8512037 1:CAS:528:DyaK3sXltlKqsLc%3D
104. S Lee W Yang KH Lan S Sellappan K Klos G Hortobagyi, et al. 2002 Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells Cancer Res 62 5703 5710 12384528 1:CAS:528:DC%2BD38XotFyksbs%3D (Pubitemid 35204725)
105. K Tanaka S Iwamoto G Gon T Nohara M Iwamoto N Tanigawa 2000 Expression of survivin and its relationship to loss of apoptosis in breast carcinomas Clin Cancer Res 6 127 134 10656440 1:CAS:528:DC%2BD3cXhtVCjsr4%3D (Pubitemid 30064984)
106. W Xia J Bisi J Strum L Liu K Carrick KM Graham, et al. 2006 Regulation of survivin by HER2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers Cancer Res 66 1640 1647 16452223 1:CAS:528:DC%2BD28XpsVemsw%3D%3D (Pubitemid 43259948)
107. P Tassone P Tagliaferri A Perricelli S Blotta B Quaresima ML Martelli, et al. 2003 BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells Br J Cancer 88 1285 1291 12698198 1:CAS:528:DC%2BD3sXivFShsr0%3D (Pubitemid 36606348)
108. M Moritz MB Braunfeld JW Sedat B Alberts DA Agard 1995 Microtubule nucleation by gamma-tubulin-containing rings in the centrosome Nature 378 638 640 8524401 1:CAS:528:DyaK2MXpvVChsbY%3D (Pubitemid 3005786)
109. S Dutertre S Descamps C Prigent 2002 On the role of aurora-A in centrosome function Oncogene 21 6175 6183 12214247 1:CAS:528: DC%2BD38Xms1yku70%3D
110. S Anand S Penrhyn-Lowe AR Venkitaraman 2003 Aurora-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to taxol Cancer Cell 3 51 62 12559175 1:CAS:528:DC%2BD3sXhtFamt7Y%3D (Pubitemid 37443890)
111. TA Brooks H Minderman KL O'Loughlin P Pera I Ojima MR Baer, et al. 2003 Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein Mol Cancer Ther 2 1195 1205 14617793 1:CAS:528:DC%2BD3sXovFCqtb0%3D
112. PM Chaudhary IB Roninson 1991 Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoieitc cells Cell 66 85 94 1712673 1:CAS:528:DyaK3MXkvVCqtbk%3D (Pubitemid 121001349)
113. T Licht I Pastan M Gottesman F Herrman 1994 P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells Ann Hematol 69 159 171 7948302 1:CAS:528:DyaK2MXis1yjtb0%3D (Pubitemid 24314384)
114. C Dumontet MA Jordan FF Lee 2009 Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies Mol Cancer Ther 8 17 25 19139109 1:CAS:528:DC%2BD1MXjvFSmtA%3D%3D
115. A Gonçalves D Braguer K Kamath L Martello C Briand S Horwitz, et al. 2001 Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics Proc Natl Acad Sci USA 98 11737 11742 11562465
116. K Fujimoto-Ouchi F Sekiguchi K Yamamoto M Shirane Y Yamashita K Mori 2010 Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy Cancer Chemother Pharmacol 66 269 276 19904537 1:CAS:528:DC%2BC3cXmt1als7k%3D
117. H Yamaguchi SR Paranawithana MW Lee Z Huang KN Bhalla HG Wang 2002 Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells Cancer Res 62 466 471 11809697 1:CAS:528:DC%2BD38XhtVyht7w%3D (Pubitemid 34106420)
118. Y Huang S Ray JC Reed AM Ibrado C Tang A Nawabi, et al. 1997 Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells Breast Cancer Res Treat 42 73 81 9116321 1:CAS:528:DyaK2sXhvV2itr0%3D (Pubitemid 27056730)
119. SH Lee SM Son DJ Son SM Kim TJ Kim S Song, et al. 2007 Epothilones induce human colon cancer SW620 cell apoptosis via the tubulin polymerization- independent activation of the nuclear factor-κB/IκB kinase signal pathway Mol Cancer Ther 6 2786 2797 17938270 1:CAS:528:DC%2BD2sXhtFKltbfK (Pubitemid 350058157)
120. C Nakahara K Nakamura N Yamanaka E Baba M Wada H Matsunaga, et al. 2003 Cyclosporine-A enhances docetaxel-induced apoptosis through inhibition of nuclear factor-κB activation in human gastric carcinoma cells Clin Cancer Res 9 5409 5416 14614027 1:CAS:528:DC%2BD3sXovVOns70%3D (Pubitemid 37413597)
121. Y Huang Y Fang JM Dziadyk JS Norris W Fan 2002 The possible correlation between activation of NF-κB/IκB pathway and the susceptibility of tumor cells to paclitaxel-induced apoptosis Oncol Res 13 113 122 12392159 1:CAS:528:DC%2BD38Xos1Wnsbg%3D (Pubitemid 38166397)
122. Y Huang Y Fang J Wu JM Dziadyk X Zhu M Sui, et al. 2004 Regulation of vinca alkaloid-induced apoptosis by NF-κB/IκB pathway in human tumor cells Mol Cancer Ther 3 271 277 15026547 1:CAS:528:DC%2BD2cXitFCns78%3D (Pubitemid 39193702)
123. JP MacKeigan TS Collins JP Ting 2000 MEK inhibition enhances paclitaxel-induced tumor apoptosis J Biol Chem 275 38953 38956 11038347 1:CAS:528:DC%2BD3cXptFSktbk%3D (Pubitemid 32058904)
124. KM Nicholson NG Anderson 2002 The protein kinase B/Akt signaling pathway in human malignancy Cell Signal 14 381 395 11882383 1:CAS:528: DC%2BD38Xhs1ylsrs%3D (Pubitemid 34214843)
125. L Fujino P Bali S Wittmann S Donapaty F Guo H Yamaguchi, et al. 2003 Histone deactylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B Mol Cancer Ther 2 971 984
126. T Sorlie R Tibshirani J Parker T Hastie JS Marron A Nobel, et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 8418 8423 12829800 1:CAS:528: DC%2BD3sXlsFGntLk%3D (Pubitemid 36842560)
127. T Sørlie CM Perou R Tibshirani T Aas S Geisler H Johnsen, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874 11553815 (Pubitemid 32878711)
128. TJ Finnegan LA Carey 2007 Gene-expression analysis and the basal-like breast cancer subtype Future Oncol 3 55 63 17280502 1:CAS:528: DC%2BD2sXjtFCgsbY%3D
129. R Rouzier CM Perou WF Symmans N Ibrahim M Cristofanilli K Anderson, et al. 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 5678 5685 16115903 1:CAS:528: DC%2BD2MXos1Cjs7k%3D (Pubitemid 41170290)
130. C Liedtke C Mazouni KR Hess F André A Tordai JA Mejia, et al. 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275 1281 18250347
131. J Baselga M Zambetti A Llombart-Cussac G Manikhas E Kubista GG Steger, et al. 2009 Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer J Clin Oncol 27 526 534 19075286 1:CAS:528:DC%2BD1MXivFyjur4%3D
132. IC Henderson DA Berry GD Demetri CT Cirrincione LJ Goldstein S Martino, et al. 2003 Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 976 983 12637460 1:CAS:528:DC%2BD2cXpsVGqs7c%3D (Pubitemid 46594124)
133. J Baselga J Albanell A Ruiz A Lluch P Gascón V Guillém, et al. 2005 Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer J Clin Oncol 23 5323 5333 15939921 1:CAS:528: DC%2BD2MXpslOrtLs%3D (Pubitemid 46206986)
134. G von Minckwitz W Jonat P Fasching A du Bois U Kleeberg HJ Lück, et al. 2005 A multicentre phase II study on geftinib in taxane- and anthracycline-pretreated metastatic breast cancer Breast Cancer Res Treat 89 165 172 1:CAS:528:DC%2BD2MXhtVamsro%3D (Pubitemid 40249050)
135. CE Geyer J Forster D Lindquist S Chan CG Romieu T Pienkowski, et al. 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743 17192538 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D (Pubitemid 46021510)
136. Y Fujiwara Y Hosokawa K Watanabe S Tanimura K Ozaki M Kohno 2007 Blockade of the phosphatidylinositol-3-kinase/Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated Mol Cancer Ther 6 1133 1142 17363506 1:CAS:528:DC%2BD2sXivV2ntL0%3D (Pubitemid 46554584)
137. J Brognard AS Clark Y Ni PA Dennis 2001 Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation Cancer Res 61 3986 3997 11358816 1:CAS:528:DC%2BD3MXktVWqsbw%3D (Pubitemid 32720961)
138. PW Baas L Qiang 2005 Neuronal microtubules: when the MAP is the roadblock Trends Cell Biol 4 183 187 (Pubitemid 40487519)
139. M Failly S Korur V Egler JL Boulay MM Lino R Imber, et al. 2007 Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells Mol Cancer Ther 6 773 781 17308073 1:CAS:528:DC%2BD2sXhvVWrtb8%3D (Pubitemid 46332478)
140. GL Semenza 2001 Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease Pediatr Res 49 614 617 11328942 1:CAS:528: DC%2BD3MXjvFKhtbo%3D (Pubitemid 32390848)
141. D Flügel A Görlach C Michiels T Kietzmann 2007 Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1α and mediates its destabilization in a VHL-independent manner Mol Cell Biol 27 3253 3265 17325032 (Pubitemid 46685205)